Intellia Therapeutics, Inc. (NASDAQ:NTLA) is set to announce third quarter earning results on Thursday 5th November 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, NTLA to report 3Q20 loss of $ 0.59 per share.
For the full year, analysts anticipate top line of $ 58.18 million, while looking forward to loss of $ 2.49 per share bottom line.
Previous Quarter Performance
Intellia Therapeutics, Inc. announced loss for the second quarter of $ 0.61 per share, from the revenue of $ 16.26 million. The quarterly revenues boosted 46.22 percent compared with the same quarter last year. The consensus estimates are loss of $ 0.69 per share from $ 8.54 million in revenue. The bottom line results beat street analysts by $ 0.08 or 11.59 percent, at the same time, top line results outshined analysts by $ 7.72 million or 90.40 percent.
Stock Performance
Shares of Intellia Therapeutics, Inc. traded up $ 1.90 or 7.52 percent on Wednesday, reaching $ 27.17 with volume of 1.03 million shares. Intellia Therapeutics, Inc. has traded high as $ 28.10 and has cracked $ 25.50 on the downward trend
The closing price of $ 27.17, representing a 175.27 % increase from the 52 week low of $ 9.18 and a 10.07 % decrease over the 52 week high of $ 28.10.
The company has a market capital of $ 1.60 billion and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 14th October 2020, initiated by Wells Fargo & Co at Overweight rating.
- On 18th September 2020, initiated by Goldman Sachs Group at Buy rating, with $ 33.00 target price.
Conference Call
Intellia Therapeutics, Inc. will be hosting a conference call at 8:00 AM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.intelliatx.com
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria. Its ex vivo pipeline includes proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune diseases; partnered programs focused on chimeric antigen receptor T cells and hematopoietic stem cells; and acute myeloid leukemia.
